Literature DB >> 30506572

Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research.

Rachel Huddart1, Alison E Fohner1,2, Michelle Whirl-Carrillo1, Genevieve L Wojcik1, Christopher R Gignoux3, Alice B Popejoy1,4, Carlos D Bustamante1,5, Russ B Altman1,5,6,7, Teri E Klein1,7,8.   

Abstract

The varying frequencies of pharmacogenetic alleles among populations have important implications for the impact of these alleles in different populations. Current population grouping methods to communicate these patterns are insufficient as they are inconsistent and fail to reflect the global distribution of genetic variability. To facilitate and standardize the reporting of variability in pharmacogenetic allele frequencies, we present seven geographically defined groups: American, Central/South Asian, East Asian, European, Near Eastern, Oceanian, and Sub-Saharan African, and two admixed groups: African American/Afro-Caribbean and Latino. These nine groups are defined by global autosomal genetic structure and based on data from large-scale sequencing initiatives. We recognize that broadly grouping global populations is an oversimplification of human diversity and does not capture complex social and cultural identity. However, these groups meet a key need in pharmacogenetics research by enabling consistent communication of the scale of variability in global allele frequencies and are now used by Pharmacogenomics Knowledgebase (PharmGKB).
© 2018 The Authors Clinical Pharmacology & Therapeutics © 2018 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Year:  2019        PMID: 30506572      PMCID: PMC6465129          DOI: 10.1002/cpt.1322

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  49 in total

1.  Population genetic structure of variable drug response.

Authors:  J F Wilson; M E Weale; A C Smith; F Gratrix; B Fletcher; M G Thomas; N Bradman; D B Goldstein
Journal:  Nat Genet       Date:  2001-11       Impact factor: 38.330

2.  The importance of race and ethnic background in biomedical research and clinical practice.

Authors:  Esteban González Burchard; Elad Ziv; Natasha Coyle; Scarlett Lin Gomez; Hua Tang; Andrew J Karter; Joanna L Mountain; Eliseo J Pérez-Stable; Dean Sheppard; Neil Risch
Journal:  N Engl J Med       Date:  2003-03-20       Impact factor: 91.245

3.  Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.

Authors:  Marjan Rahsaz; Negar Azarpira; Saman Nikeghbalian; Mahdokht H Aghdaie; Bita Geramizadeh; Maryam Moini; Mehrzad Banihashemi; Masumeh Darai; Zahra Malekpour; Seid Ali Malekhosseini
Journal:  Exp Clin Transplant       Date:  2012-02       Impact factor: 0.945

4.  Genomics for the world.

Authors:  Carlos D Bustamante; Esteban González Burchard; Francisco M De la Vega
Journal:  Nature       Date:  2011-07-13       Impact factor: 49.962

5.  RFMix: a discriminative modeling approach for rapid and robust local-ancestry inference.

Authors:  Brian K Maples; Simon Gravel; Eimear E Kenny; Carlos D Bustamante
Journal:  Am J Hum Genet       Date:  2013-08-01       Impact factor: 11.025

6.  Pathogenic variants for Mendelian and complex traits in exomes of 6,517 European and African Americans: implications for the return of incidental results.

Authors:  Holly K Tabor; Paul L Auer; Seema M Jamal; Jessica X Chong; Joon-Ho Yu; Adam S Gordon; Timothy A Graubert; Christopher J O'Donnell; Stephen S Rich; Deborah A Nickerson; Michael J Bamshad
Journal:  Am J Hum Genet       Date:  2014-07-31       Impact factor: 11.025

7.  Second-generation PLINK: rising to the challenge of larger and richer datasets.

Authors:  Christopher C Chang; Carson C Chow; Laurent Cam Tellier; Shashaank Vattikuti; Shaun M Purcell; James J Lee
Journal:  Gigascience       Date:  2015-02-25       Impact factor: 6.524

8.  A global reference for human genetic variation.

Authors:  Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

9.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.

Authors:  J A Johnson; K E Caudle; L Gong; M Whirl-Carrillo; C M Stein; S A Scott; M T Lee; B F Gage; S E Kimmel; M A Perera; J L Anderson; M Pirmohamed; T E Klein; N A Limdi; L H Cavallari; M Wadelius
Journal:  Clin Pharmacol Ther       Date:  2017-04-04       Impact factor: 6.875

10.  Estimation of the warfarin dose with clinical and pharmacogenetic data.

Authors:  T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

View more
  26 in total

1.  High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms.

Authors:  Andrew A Somogyi; Daniel T Barratt; Elizabeth J Phillips; Kylies Moore; Fahmida Ilyas; Genevieve M Gabb
Journal:  Br J Clin Pharmacol       Date:  2019-07-19       Impact factor: 4.335

Review 2.  The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation?

Authors:  Honghong Zhang; Tanima De; Yizhen Zhong; Minoli A Perera
Journal:  Clin Pharmacol Ther       Date:  2019-08       Impact factor: 6.875

3.  Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population.

Authors:  Shana S Jacobs; Jeffrey S Dome; Jiaxiang Gai; Andrea M Gross; Elena Postell; Pamela S Hinds; Lionel Davenport; John N van den Anker; Catriona Mowbray
Journal:  Support Care Cancer       Date:  2022-01-11       Impact factor: 3.603

Review 4.  PharmVar GeneFocus: CYP2D6.

Authors:  Charity Nofziger; Amy J Turner; Katrin Sangkuhl; Michelle Whirl-Carrillo; José A G Agúndez; John L Black; Henry M Dunnenberger; Gualberto Ruano; Martin A Kennedy; Michael S Phillips; Houda Hachad; Teri E Klein; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-12-09       Impact factor: 6.875

Review 5.  PharmVar GeneFocus: CYP2C19.

Authors:  Mariana R Botton; Michelle Whirl-Carrillo; Andria L Del Tredici; Katrin Sangkuhl; Larisa H Cavallari; José A G Agúndez; Jorge Duconge; Ming Ta Michael Lee; Erica L Woodahl; Karla Claudio-Campos; Ann K Daly; Teri E Klein; Victoria M Pratt; Stuart A Scott; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2020-07-22       Impact factor: 6.875

Review 6.  Health equality, race and pharmacogenomics.

Authors:  Emma F Magavern; Deepti Gurdasani; Fu L Ng; Sandra Soo-Jin Lee
Journal:  Br J Clin Pharmacol       Date:  2021-08-04       Impact factor: 4.335

7.  CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications.

Authors:  Anna Mueller-Schoell; Robin Michelet; Ferdinand Weinelt; Charlotte Kloft; Gerd Mikus
Journal:  Arch Toxicol       Date:  2021-05-24       Impact factor: 5.153

Review 8.  Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy.

Authors:  Victoria M Pratt; Larisa H Cavallari; Andria L Del Tredici; Andrea Gaedigk; Houda Hachad; Yuan Ji; Lisa V Kalman; Reynold C Ly; Ann M Moyer; Stuart A Scott; R H N van Schaik; Michelle Whirl-Carrillo; Karen E Weck
Journal:  J Mol Diagn       Date:  2021-06-10       Impact factor: 5.341

Review 9.  PharmVar GeneFocus: CYP2C9.

Authors:  Katrin Sangkuhl; Karla Claudio-Campos; Larisa H Cavallari; Jose A G Agundez; Michelle Whirl-Carrillo; Jorge Duconge; Andria L Del Tredici; Mia Wadelius; Mariana Rodrigues Botton; Erica L Woodahl; Stuart A Scott; Teri E Klein; Victoria M Pratt; Ann K Daly; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2021-07-12       Impact factor: 6.903

10.  Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups.

Authors:  Anna Mueller-Schoell; Robin Michelet; Lena Klopp-Schulze; Madelé van Dyk; Thomas E Mürdter; Matthias Schwab; Markus Joerger; Wilhelm Huisinga; Gerd Mikus; Charlotte Kloft
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.